Latest news with #Amgen
Yahoo
4 days ago
- Business
- Yahoo
Amgen's Strong Cash Flow Supports Reliable Dividend Payments
Amgen Inc. (NASDAQ:AMGN) is one of the . The company has built a solid track record of dividend growth, supported by consistent cash generation. In the first quarter of 2025, it generated $1.0 billion in free cash flow, up from $0.5 billion in the same period of 2024. The increase was partly due to a one-time $800 million tax payment made in Q1 2024, along with improved business performance, though partially offset by working capital timing and higher capital spending. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN)'s operating cash flow for the quarter rose to $1.4 billion, compared to $0.7 billion a year earlier. During this period, the company returned $1.3 billion to shareholders through dividends, highlighting its ongoing focus on delivering value. As of March 31, 2025, the company held $8.8 billion in cash and cash equivalents, with total debt standing at $57.4 billion. Alongside its consistent dividend growth, Amgen Inc. (NASDAQ:AMGN) stands out as a strong dividend contender due to its modest payout ratio of 44%. This indicates it distributes a sustainable portion of its earnings as dividends while maintaining financial flexibility. Despite significant investments in research and development, the company manages to reward shareholders without straining its balance sheet. Since initiating its dividend in 2011, the company has increased its payout every year. Over the past ten years, the dividend has grown by an impressive 201.3%. It offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.22%, as of June 14. Amgen Inc. (NASDAQ:AMGN) is focused on discovering, developing, producing, and delivering cutting-edge medicines that support millions of patients in battling some of the most challenging diseases worldwide. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial
Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine. It showed that IMDELLTRA reduced the risk of death by 40% and extended median overall survival by over 5 months compared to standard-of-care/SOC chemotherapy in patients with small cell lung cancer/SCLC who had progressed on or after one line of platinum-based chemotherapy. IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen. A pharmacist filling a prescription for a complex drug developed by the company. It binds to DLL3, which is a protein expressed on the surface of SCLC cells in ~85-96% of patients but minimally on healthy cells, and CD3 on T-cells. This dual binding activates T-cells to specifically target and kill DLL3-expressing SCLC cells. The DeLLphi-304 trial is a global Phase 3, randomized, controlled, and open-label clinical study. It enrolled 509 patients. The results support the potential conversion of IMDELLTRA's accelerated FDA approval, which was granted last year based on tumor response rates, into a full approval. Amgen Inc. (NASDAQ:AMGN) discovers, develops, and manufactures human therapeutics globally. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Globe and Mail
4 days ago
- Business
- Globe and Mail
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called Innovative Medicine. Under this segment, J&J markets several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases. J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. A biosimilar version of J&J's multi-billion-dollar immunology drug, Stelara, was launched in certain European markets for some indications in July 2024. Several biosimilar versions of Stelara are expected to be launched in the United States in 2025, according to patent settlements and license agreements. Amgen AMGN launched the first Stelara biosimilar, Wezlana, in January 2025, while Teva launched Selarsdi in February 2025. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. Stelara sales are expected to come down from almost $11 billion in 2023 to around $2.9 billion in 2027, per our estimates. However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new cancer drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects to generate more than $57 billion in sales in the Innovative Medicine segment in 2025. It expects the Innovative Medicine business to grow 5-7% from 2025 to 2030. J&J Key Competitors Immunology and oncology are J&J's key areas. Other large drugmakers holding a strong presence in the oncology market are Novartis, AstraZeneca, AbbVie ABBV, Merck, Bristol-Myers, Roche and Pfizer PFE. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 10.4% in the year-to-date period compared with an increase of 4.0% for the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.58 forward earnings, slightly lower than 15.65 for the industry. The stock is also trading below its five-year mean of 15.76. The stock is cheaper than some other drugmakers like AbbVie, Lilly and Novo Nordisk. The Zacks Consensus Estimate for 2025 earnings has risen from $10.51 per share to $10.60 over the past 60 days, while that for 2026 has declined from $10.99 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
Yahoo
13-06-2025
- Health
- Yahoo
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he experienced a heart attack on Father's Day in 2024 and what he's learned since then about high LDL or "bad" cholesterol—a leading, but often hidden risk factor for cardiovascular events.2-7 "I've spent my life as a professional athlete taking care of my body, but I had no idea I was living with a silent risk that could lead to a heart attack," said Sanders. "My message to other people is simple: don't wait. Get your LDL-C tested and talk to your doctor. Knowing your number is an important step to understanding your risk."7 More than 40% of adults with high LDL-C in the U.S. do not know their levels are high.8 The documentary educates viewers about LDL-C and how it can lead to a buildup of plaque in the arteries, putting individuals at risk of a cardiovascular event.5 "We know that high LDL-C is one of the leading, yet most modifiable, risk factors for heart attack and stroke.1 However, the cardiovascular disease public health crisis continues," said Paul Burton, M.D., senior vice president and chief medical officer at Amgen. "The Making of a Heart Attack should be a wake-up call for everyone. Amgen is committed to leading change by increasing LDL-C testing and encouraging patients and the entire healthcare system to act with urgency to overcome inertia and address this issue." Featured alongside Sanders sharing their own stories of living with cardiovascular disease are Hyvelle Ferguson-Davis, founder of Heart Sistas; Tara Robinson, CEO of the Black Heart Association; Gigi Campos, a WomenHeart Champion; and her father, Ponciano Gari. Sara Collins, M.D., FACC, an interventional cardiologist and member of the Association of Black Cardiologists, provides her expert medical perspective throughout. The documentary is part of Amgen's broader ambition to cut the number of heart attacks and strokes in the U.S. in half by 2030. Working with advocacy leaders, medical societies, healthcare systems and research institutions, Amgen is advancing efforts to drive earlier LDL-C testing, expand access to care and improve health outcomes. Watch The Making of a Heart Attack on June 14, 2025, at 1 p.m. ET on A&E (check local listings). The documentary will be available to watch online at beginning June 16, 2025 and will be featured at the Cannes Lions International Festival of Creativity 2025. To learn more about LDL-C, especially if you have cardiovascular disease, including how to get a free cholesterol test, visit Be sure to talk to your doctor about your results. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads. Amgen Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed, and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media) Justin Claeys, 805-313-9775 (investors) REFERENCES Martin SS, et al. Circulation. 2024;149:e347-e913. Grundy SM, et al. J Am Coll Cardiol. 2019;73:3168-3209. McKinley EC, et al. Cardiovasc Drugs Ther. 2023;37:107-116. Wilkinson MJ, et al. J Am Heart Assoc. 2023;12:11:e028892:1-22. Understanding and Managing LDL (Bad) Cholesterol. American Heart Association. Accessed June 2025. Underberg J, et al. Postgrad Med. 2022;134:752-762. Heart Disease Risk Factors. Centers for Disease Control and Prevention. December 2, 2024. Accessed June 2025. Sayed A, et al. JAMA Cardiol. 2023;8(12):1185–1187. View original content: SOURCE Amgen Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Amgen Inc. (NASDAQ:AMGN) does have debt on its balance sheet. But should shareholders be worried about its use of debt? This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we think about a company's use of debt, we first look at cash and debt together. You can click the graphic below for the historical numbers, but it shows that Amgen had US$57.4b of debt in March 2025, down from US$64.0b, one year before. On the flip side, it has US$8.81b in cash leading to net debt of about US$48.6b. According to the last reported balance sheet, Amgen had liabilities of US$23.0b due within 12 months, and liabilities of US$60.2b due beyond 12 months. On the other hand, it had cash of US$8.81b and US$8.13b worth of receivables due within a year. So its liabilities total US$66.2b more than the combination of its cash and short-term receivables. While this might seem like a lot, it is not so bad since Amgen has a huge market capitalization of US$156.9b, and so it could probably strengthen its balance sheet by raising capital if it needed to. However, it is still worthwhile taking a close look at its ability to pay off debt. See our latest analysis for Amgen We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio). Amgen has a debt to EBITDA ratio of 3.1 and its EBIT covered its interest expense 3.4 times. Taken together this implies that, while we wouldn't want to see debt levels rise, we think it can handle its current leverage. Fortunately, Amgen grew its EBIT by 9.9% in the last year, slowly shrinking its debt relative to earnings. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Amgen can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts. But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. During the last three years, Amgen generated free cash flow amounting to a very robust 88% of its EBIT, more than we'd expect. That positions it well to pay down debt if desirable to do so. When it comes to the balance sheet, the standout positive for Amgen was the fact that it seems able to convert EBIT to free cash flow confidently. However, our other observations weren't so heartening. For example, its interest cover makes us a little nervous about its debt. Considering this range of data points, we think Amgen is in a good position to manage its debt levels. But a word of caution: we think debt levels are high enough to justify ongoing monitoring. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should be aware of the 1 warning sign we've spotted with Amgen . When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
